Home > Press Room > Press Releases

Bioponic Phytoceuticals Announces Research Agreement With Pediatric Neurosurgery and Childhood Hydrocephalus Center's Dr. J. Pattisapu.

MAUI, HAWAII, Date: July 27, 2006 /PRNewswire- /

Bioponic Phytoceuticals, Inc. ("Bioponic" or "the Company") (OTC: BPYT - News) today announced that it has signed an agreement with Pediatric Neurosurgery and Childhood Hydrocephalus Center's principal Dr. Jogi Pattisapu to research a treatment for Childhood Hydrocephalus using the Company's Curecumin(TM) product.

Bioponic Phytoceuticals' Curecumin product is the first Bioresonant Phytotherapeutic(TM) formula of curcumin, the active ingredient found in Turmeric root. Curcumin has been found an effective treatment for Cisttic Fibrosis, "It can almost completely correct the measurable defects of the disease," says Michael Caplan at Yale University in New Haven, Connecticut, (Science, vol 304, p 600), and various cancers, "we conclude curcumin is a potent suppressor of cell viability and inducer of apoptosis in melanoma cell lines," says B. Aggarwal of University of Texas M.D. Anderson Cancer Center in Houston. "Curcumin is considered to be a potent cancer chemopreventive agent," (Baum and Ng, 2004; Eybl et al., 2006)," and is recognized by Dr. Pattisapu as a potential candidate for treating Childhood Hydrocephalus.

Dr. Jogi Pattisapu is a practicing pediatric neurosurgen and principal of Pediatric Neurosurgery and Childhood Hydrocephalus Center of Orlando, Florida. He is currently researching advanced treatments for Childhood Hydrocephalus in order to find alternatives to the shunt brain surgeries that are the currently accepted treatment for this ailment.

"The opportunity to participate in potentially ground breaking research into the treatment of an ailment that effects over 500,000 children will open up new possibilities for marketing the Company's innovative products into the medical biotech arena," said Steven M. Schorr, Chairman & CEO - Bioponic Phytoceuticals, Inc.

Bioponic Phytoceuticals is engaged in the formulation, production and distribution of Bioresonant Phytotherapeutic(TM) products for sale in the Complementary Alternative Medicine and natural products markets. The Company has developed a new patent pending healing modality "Bioresonant Phytotherapeutics" and has several branded product lines currently in national distribution (including the noted natural nasal spray: Flight Spray®). www.bioponic.com, and www.flightspray.com

Contact: Steven M. Schorr, CEO
Bioponic Phytoceuticals
info@bioponic.com
phone: 808-876-1711


Certain statements contained in this press release are forward-looking statements within the meaning of federal securities laws.

NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS RELEASE. THE PINK SHEETS LLC DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.